By: Tony Hagen
The United States Pharmacopeial Convention (USP) General Chapter is a good start for improving the protection of healthcare workers exposed to hazardous drugs, but more studies and safety protocols are needed, according to an American Society of Clinical Oncology (ASCO) expert panel that evaluated USP and various other guidelines in a report last year.
By: Sarah M. C. Sittenfeld, MD
Neoadjuvant stereotactic radiosurgery has gained interest. This approach allows for easier target delineation; a smaller margin of normal brain parenchymal receiving the radiosurgery dose, which may decrease toxicity; and the potential to reduce the risk of leptomeningeal disease by sterilizing the tumor margin preoperatively.
By: Maurie Markman, MD
The cancer treatment community's ultimate perception of a successfully completed phase III randomized trial depends in large part on how well the trial was conceived and structured. To permit adequate accrual in a timely manner and optimize the chances for a study to achieve success, the question it poses must be relevant to ensure interest by clinical investigators, referring clinicians, and potential research subjects. Further, the initiative must have adequate funding for data collection and analysis, translational laboratory investigations, and other trial components.
By: Rachel Narozniak, MA
Investigators will challenge therapeutic convention by testing a PARP inhibitor instead of an IDH-targeted therapy in patients with metastatic IDH1/2-mutated glioma, cholangiocarcinoma, and other solid tumors that are refractory to standard treatment.